Message

Ina Research Inc. joined the SNBL (Shin Nippon Biomedical Laboratories) Group in August of 2022, a move that empowered us to offer an even wider range of technologies and services along with enhanced flexibility.

With the increase in demand for the latest testing methods and analyses in pharmaceutical development, we have been actively assimilating these rapidly evolving innovative technologies to accommodate the needs of our clients. Regarding our services, we excel at safety studies for advanced technologies such as small molecules, biopharmaceuticals and gene therapies; advanced analytics such as imaging; SEND, our long-held strength; and support for regulatory submission. We conduct nonclinical studies required for the development of test products including not only pharmaceuticals but also medical devices, regenerative medical products, pesticides and chemical substances, all in full compliance with the latest regulations.

As a CRO that puts ourselves in the shoes of our clients, we will always strive for continual improvement to provide you the best support in an ever-changing industry. We hope you will give us the privilege of continuing to serve you in the future.

Terumasa Hirai
President, Chief Executive Officer
Ina Research Inc.